Yokota, Etsuko
Iwai, Miki
Ishida, Yuta
Yukawa, Takuro
Matsubara, Masaki
Naomoto, Yoshio
Fujiwara, Hideyo
Monobe, Yasumasa
Haisa, Minoru
Takigawa, Nagio
Fukazawa, Takuya http://orcid.org/0000-0003-2890-0599
Yamatsuji, Tomoki
Funding for this research was provided by:
The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (22H03164)
Article History
Received: 8 April 2024
Accepted: 27 May 2024
First Online: 3 June 2024
Declarations
:
: T. Yamatsuji reports grants from MSD, Chugai Pharmaceutical, Takeda Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Kaken Pharmaceutical Co., Ltd., Astellas Pharma Inc., Eli Lilly Japan, Shionogi Pharma Co., Ltd., Taiho Pharmaceutical, Bayer Yakuhin, Ltd., and Otsuka Pharmaceutical Co., Ltd., and personal fees from Yakult Honsha Co., Ltd. outside the submitted work. N. Takigawa reports grants and personal fees from Eli Lilly Japan, AstraZeneca, Daiichi-Sankyo Co., Ltd., Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer Inc., Japan, Boehringer-Ingelheim Japan, and Ono Pharmaceutical; grants from Kyowa Hakko Kirin, Nippon Kayaku Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; and personal fees from MSD and Bristol-Myers Squibb Company, Japan, outside the submitted work. Fukazawa reports personal fees from Boehringer Ingelheim, Japan. No disclosures were reported by the other authors.
: The research protocol was approved by the Ethics Committee of the Kawasaki Medical School (Reference Number: 3171-6). All studies involving animals were approved by the Animal Research Committee of Kawasaki Medical School (Reference Number: 23-047). The care and use of animals were conducted in accordance with the committee regulations.
: Patients who participated in the study signed an informed consent form approved by the responsible authority.